Pfizer may be the last major oncology player to put a wager on a PARP inhibitor in prostate cancer, but the New York pharma appears to have a winning regimen, partly thanks to its Astellas-partnered ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Study Overview: Pfizer Inc. is conducting a Korea Post Marketing ...

First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic ...

Pfizer’s prostate cancer therapy Talzenna, when combined with Xtandi, can extend overall survival (OS) by nearly nine months over the standard of care (SoC), according to a Phase III trial. The US ...

The PARP inhibitor class is welcoming its second FDA approval in prostate cancer in the span of several weeks. The new approval, for Pfizer, is broader than the first but still limited. The FDA has ...

Talzenna (talazoparib) is a brand-name drug that’s prescribed for certain types of breast and prostate cancers in adults. It comes as an oral capsule that’s typically taken once per day. The dosage ...

Pfizer’s Talzenna (talazoparib) has become the first targeted treatment to be recommended by the National Institute for Health and Care Excellence (NICE) to treat HER2-negative locally advanced or ...

Credit: Pfizer. Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or ...